Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01

被引：27
|
作者：
Javle, Milind M.
Abou-Alfa, Ghassan K.
Macarulla, Teresa
Personeni, Nicola
Adeva, Jorge
Bergamo, Francesca
Malka, David
Vogel, Arndt
Knox, Jennifer J.
Evans, T. R. Jeffry
Dimova-Dobreva, Miryana
Harris, William Proctor
Saulay, Mikael
Engelhardt, Marc
Braun, Stephan
Busset, Michele Droz Dit
Borad, Mitesh J.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Cornell Univ, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Cornell Univ, Weill Med Coll, New York, NY 10021 USA
[4] Hosp Univ Vall dHebron, Barcelona, Spain
[5] Ist Clin Humanitas, Humanitas Canc Ctr, Rozzano, Italy
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Oncol 1, Padua, Italy
[8] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy, Villejuif, France
[9] Hannover Med Sch, Hannover, Germany
[10] Univ Hlth Network, Wallace McCain Ctr Pancreat Canc, Princess Margaret Canc Ctr, Toronto, ON, Canada
[11] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[12] Basilea Pharmaceut Int Ltd, Basel, NJ, Switzerland
[13] Univ Washington, Seattle Canc Care Alliance SCCA, Seattle, WA 98195 USA
[14] Natl Inst Canc, Dept Hepatopancreatobiliary Surg & Liver Transpla, Milan, Italy
[15] Mayo Clin, Ctr Canc, Scottsdale, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.427
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
427
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Efficacy and safety of pemigatinib in Chinese patients with unresectable, advanced/recurrent or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement that failed to prior systemic therapy
    Shi, G-M.
    Huang, X-Y.
    Wen, T-F.
    Song, T-Q.
    Kuang, M.
    Mou, H-B.
    Bao, L-Q.
    Zhao, H-T.
    Zhao, H.
    Feng, X-L.
    Zhang, B.
    Peng, T.
    Zhang, Y.
    Li, X.
    Yu, H.
    Cao, Y.
    Luo, Y.
    Wang, Y.
    Fan, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S377 - S377
  • [42] Safety and efficacy of efpegerglucagon in patients with congenital hyperinsulinism: interim results from a phase 2 study
    Dastamani, Antonia
    Banerjee, Indraneel
    Mohnike, Klaus
    Puri, Mala
    Gwak, Eunji
    Kang, Seohyun
    Byeon, JinHee
    Lee, Moon Hee
    De Leon, Diva
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 319 - 319
  • [43] COST-EFFECTIVENESS OF PEMIGATINIB FOR PATIENTS WITH ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA AND FGFR2 FUSIONS/ REARRANGEMENTS: 2024 FIGHT-202 TRIAL FINAL RESULTS
    Huang, W. M.
    Wang, I. T.
    Chen, H. L.
    Chueh, C. H.
    Chiang, N. J.
    Tsai, Y. W.
    VALUE IN HEALTH, 2024, 27 (12)
  • [44] A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Xu, Jianming
    Xiong, Jianping
    Gu, Shanzhi
    Niu, Zuoxing
    Yin, Fei
    Sun, Beicheng
    Zhang, Lan
    Zhou, Fuxiang
    Hao, Chunyi
    Pan, Yueyin
    Qiu, Wensheng
    Gao, Yi
    Ren, Yongxin
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Javle, M.
    Kelley, R. K.
    Roychowdhury, S.
    Weiss, K. H.
    Abou-Alfa, G. K.
    Macarulla, T.
    Sadeghi, S.
    Waldschmidt, D.
    Zhu, A. X.
    Goyal, L.
    Borad, M.
    Yong, W. P.
    Borbath, I.
    El-Khoueiry, A.
    Philip, P.
    Moran, S.
    Ye, Y.
    Ising, M.
    Lewis, N.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
  • [46] Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2-A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements
    Valle, J. W.
    Hollebecque, A.
    Furuse, J.
    Goyal, L.
    Meric-Bernstam, F.
    Morlock, R.
    He, Y.
    Benhadji, K.
    Bridgewater, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S263 - S264
  • [47] Foenix-CCA2 quality of life data for Futibatinib-treated intrahepatic cholangiocarcinoma (ICCA) patients with FGFR2 fusions/rearrangements
    Moehler, M.
    Valle, J. W.
    Hollebecque, A.
    Furuse, J.
    Goyal, L.
    Meric-Bernstam, F.
    Epstein, R.
    Salimi, T.
    Wacheck, V
    Liu, M.
    Benhadji, K. A.
    Bridgewater, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 223 - 224
  • [48] Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis
    Javle, M.
    Sadeghi, S.
    Roychowdhury, S.
    El-Khoueiry, A.
    Goyal, L.
    Philip, P.
    Kelley, R.
    Borbath, I.
    Macarulla, T.
    Yong, W.
    Tanasanvimon, S.
    Li, A.
    Howland, M.
    Pande, A.
    Abou-Alfa, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S219 - S219
  • [49] First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors
    Goyal, L.
    Subbiah, V.
    Mahipal, A.
    Kamath, S.
    Mody, K.
    Borad, M.
    El-Khoueiry, A.
    Sahai, V.
    Kim, R.
    Kelley, R.
    Schmidt-Kittler, O.
    Shen, J.
    Jen, K.
    Deary, A.
    Padval, M.
    Sherwin, C.
    Wolf, B.
    Schram, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S120 - S120
  • [50] FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
    Goyal, Lipika
    Meric-Bernstam, Funda
    Hollebecque, Antoine
    Valle, Juan W.
    Morizane, Chigusa
    Karasic, Thomas Benjamin
    Furuse, Junji
    He, Yaohua
    Soni, Nital
    Benhadji, Karim A.
    Bridgewater, John A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345